While not a direct report of GATA-3 findings, it emphasizes the integration of comprehensive metabolic profiling—including insulin sensitivity and body composition—alongside traditional inflammatory and respiratory metrics in randomized controlled asthma trials. The gene discussed is INS; the disease is asthma.